Drug Trial Radar · NCT05198323
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Aug 11, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Lumosa Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase IIb clinical study to evaluate the safety and efficacy of single or multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).
Conditions
- Acute Ischemic Stroke
Interventions
LT3001 Drug ProductDrug
LT3001 Drug Product administered once by intravenous infusion
PlaceboDrug
Placebo administered once by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The occurrence of symptomatic intracranial hemorrhage within 24 hours after the single dosing; clinical deterioration defined as an change in the NIHSS of 4 points or more and confirmed by MRITime frame: Within 24 hours
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
CHI Memorial Hospital
Chattanooga, Tennessee
Taichung Medical University
Taichung, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.